Efflux of glutathione and glutathione complexes from human erythrocytes in response to inorganic arsenic exposure.
The objective of the present study was to investigate if arsenic exposure results in glutathione efflux from human erythrocytes. Arsenite significantly depleted intracellular nonprotein thiol level in a time- and concentration-dependent manner. The intracellular nonprotein thiol level was decreased to 0.767 ± 0.0017 μmol/ml erythrocyte following exposure to 10 mM of arsenite for 4 h. Extracellular nonprotein thiol level was increased concomitantly with the intracellular decrease and reached to 0.481 ± 0.0005 μmol/ml erythrocyte in 4 h. In parallel with the change in extracellular nonprotein thiol levels, significant increases in extracellular glutathione levels were detected. Extracellular glutathione levels reached to 0.122 ± 0.0013, 0.226 ± 0.003, and 0.274 ± 0.004 μmol/ml erythrocyte with 1, 5, and 10 mM of arsenite, respectively. Dimercaptosuccinic acid treatment of supernatants significantly increased the glutathione levels measured in the extracellular media. Utilization of MK571 and verapamil, multidrug resistance-associated protein 1 and Pgp inhibitors, decreased the rate of glutathione efflux from erythrocytes suggesting a role for these membrane transporters in the process. The results of the present study indicate that human erythrocytes efflux glutathione in reduced free form and in conjugated form or forms that can be recovered with dimercaptosuccinic acid when exposed to arsenite.
Faculty of Arts and Science, Biology Department, Mustafa Kemal University, 31000, Antakya, Turkey. dyildiz@mku.edu.tr
Deniz
D
Yildiz
Yeliz
Y
Cakir
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D001149:Arsenates / Q000037:antagonists & inhibitors / Q000494:pharmacology; D001152:Arsenicals / Q000494:pharmacology*; D018053:Arsenites / Q000037:antagonists & inhibitors / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects; D001711:Biotransformation / Q000187:drug effects; D002614:Chelating Agents / Q000494:pharmacology; D017077:Culture Media, Conditioned / Q000378:metabolism; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000378:metabolism; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism; D005978:Glutathione / Q000031:analogs & derivatives / Q000378:metabolism*; D006801:Humans; D049990:Membrane Transport Modulators / Q000494:pharmacology; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D009994:Osmolar Concentration; D010084:Oxidation-Reduction; D017670:Sodium Compounds / Q000037:antagonists & inhibitors / Q000494:pharmacology; D013438:Sulfhydryl Compounds / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013696:Temperature
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D001149:Arsenates; D001152:Arsenicals; D018053:Arsenites; D002614:Chelating Agents; D017077:Culture Media, Conditioned; D005978:Glutathione; D049990:Membrane Transport Modulators; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D017670:Sodium Compounds; D013438:Sulfhydryl Compounds; C513055:ABCB1 protein, human; C017947:sodium arsenite; C009277:sodium arsenate; C421109:multidrug resistance-associated protein 1